List of Excipients in Branded Drug LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

Generic Drugs Containing LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

Company	Ingredient	NDC	Excipient
Henry Schein Inc	lidocaine hydrochloride and epinephrine	0404-9788	ANHYDROUS CITRIC ACID
Henry Schein Inc	lidocaine hydrochloride and epinephrine	0404-9788	HYDROCHLORIC ACID
Henry Schein Inc	lidocaine hydrochloride and epinephrine	0404-9788	METHYLPARABEN
Henry Schein Inc	lidocaine hydrochloride and epinephrine	0404-9788	SODIUM CHLORIDE
Henry Schein Inc	lidocaine hydrochloride and epinephrine	0404-9788	SODIUM HYDROXIDE
Henry Schein Inc	lidocaine hydrochloride and epinephrine	0404-9788	SODIUM METABISULFITE
Henry Schein Inc	lidocaine hydrochloride and epinephrine	0404-9788	WATER

What are the Most Frequently-Used Excipients in LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE?

# Of NDCs	Excipient
10	ANHYDROUS CITRIC ACID
1	CITRIC ACID ANHYDROUS
11	HYDROCHLORIC ACID
10	METHYLPARABEN
12	SODIUM CHLORIDE
11	SODIUM HYDROXIDE
12	SODIUM METABISULFITE

Lidocaine Hydrochloride and Epinephrine Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 16, 2026

Lidocaine hydrochloride and epinephrine is an established local-anesthetic combination with limited molecule-level exclusivity and substantial opportunity in presentation, preservative design, device integration, and supply reliability. The main excipient challenge is controlling epinephrine oxidation while maintaining lidocaine solubility, injection compatibility, sterility, and acceptable local tolerability. The strongest commercial opportunities are preservative-free unit-dose formats, ready-to-use syringes and cartridges, lower-concentration epinephrine presentations, and differentiated products for dental, emergency, dermatologic, and minor surgical procedures.

What is the FDA status of lidocaine hydrochloride and epinephrine?

Lidocaine hydrochloride and epinephrine injection is an FDA-approved prescription combination used for local or regional anesthesia when prolongation of anesthesia and reduction of systemic absorption are clinically useful. Lidocaine is the local anesthetic; epinephrine produces local vasoconstriction and can extend anesthetic duration while reducing bleeding.

Common labeled strengths include:

Lidocaine HCl concentration	Epinephrine concentration	Typical presentation
0.5%	1:200,000	Injection
1%	1:100,000 or 1:200,000	Injection, dental cartridges, vials
1.5%	1:200,000	Injection
2%	1:100,000 or 1:200,000	Injection, dental cartridges, vials

The exact available strengths differ by manufacturer and dosage form. FDA labeling identifies the products as sterile injections for infiltration, nerve block, epidural, or other regional anesthetic techniques, subject to product-specific labeling.[1]

The combination is a small-molecule drug product rather than a biologic. Biosimilar regulation does not apply. Generic competition proceeds primarily through abbreviated new drug applications, with pharmaceutical-equivalence and bioequivalence requirements tailored to the injectable product.

What excipients are used in lidocaine and epinephrine injections?

The central excipient system normally includes a tonicity agent, an antioxidant or sulfite stabilizer, pH adjustment agents, and, in some multidose products, a preservative.

Excipient function	Common materials	Strategic purpose
Tonicity adjustment	Sodium chloride	Reduces injection discomfort and supports isotonicity
Antioxidant protection	Sodium metabisulfite or sodium bisulfite	Limits epinephrine oxidation
pH adjustment	Hydrochloric acid, sodium hydroxide	Controls stability, solubility, and tolerability
Antimicrobial preservation	Methylparaben or related preservative	Supports multidose packaging
Vehicle	Water for Injection	Sterile injectable medium
Chelation, where justified	Edetate salts or other chelators	May reduce trace-metal catalyzed oxidation

Product-specific labels must control the final excipient selection. DailyMed listings show that formulations vary by manufacturer, strength, package size, and whether the product is single-dose or multidose.[2]

Why is sodium metabisulfite important?

Epinephrine is highly vulnerable to oxidation. Oxidation can produce adrenochrome and other degradation products, causing pink, red, or brown discoloration and reducing potency. Sulfite antioxidants are therefore common in epinephrine-containing injections.

The commercial tradeoff is clinically important. Sulfite-containing products can cause hypersensitivity reactions, particularly in susceptible patients with asthma. The product label must identify the sulfite and carry the relevant warning.[1] A sulfite-free epinephrine formulation would have a clear differentiation claim, but it would require a credible alternative stabilization system and robust stability data.

How does pH affect the formulation?

Lidocaine hydrochloride is water-soluble in its salt form. Epinephrine stability, lidocaine solubility, injection-site tolerability, and preservative performance all depend on pH. Excessively acidic formulations may increase injection discomfort, while higher pH can accelerate epinephrine degradation or cause precipitation under certain conditions.

A practical development strategy is to define a narrow pH range based on:

• Epinephrine assay and impurity growth.
• Lidocaine clarity and precipitation risk.
• Container-closure compatibility.
• Sterilization exposure.
• Injection-site tolerability.
• Stability after dilution or transfer into procedural devices.

The formulation should be evaluated under both refrigerated and controlled-room-temperature conditions, with specific attention to light exposure and oxygen headspace.

What excipient strategy is strongest for commercial development?

The best excipient strategy depends on the target market rather than on a single universal formulation.

Preservative-free unit-dose strategy

A preservative-free formulation is attractive for neuraxial, ophthalmic-adjacent, pediatric, and high-sensitivity use cases where avoidance of methylparaben is commercially relevant. The product can be packaged in single-dose vials, ampoules, or prefilled syringes.

Advantages include:

• Lower concern about preservative-related intolerance.
• Better positioning for single-patient, single-procedure use.
• Potential fit with hospital medication-safety programs.
• Reduced risk of preservative accumulation in repeated procedures.

The tradeoff is higher packaging cost and the need for strict aseptic manufacturing controls. The absence of a preservative does not permit reuse of a single-dose container.

Multidose strategy

A multidose vial with a compatible antimicrobial preservative can reduce per-dose acquisition cost for high-throughput dental and outpatient settings. Methylparaben has been used in some injectable local-anesthetic products, but its inclusion creates a differentiation disadvantage where preservative-free alternatives are preferred.

Multidose products require close attention to:

• Preservative concentration and effectiveness.
• Container puncture performance.
• In-use stability.
• Stopper compatibility.
• Extractables and leachables.
• Labeling that limits reuse and handling.

Sulfite-reduced or sulfite-free strategy

A sulfite-reduced or sulfite-free product could target patients and institutions seeking to avoid sulfite exposure. The formulation would need an alternative approach, potentially involving:

• Oxygen-control packaging.
• Low-oxygen filling.
• Light-protective containers.
• Chelation.
• Optimized pH.
• Nitrogen or argon headspace.
• Alternative antioxidant systems.

A sulfite-free claim would have to be supported by long-term, accelerated, photostability, in-use, and shipping data. The principal development risk is maintaining epinephrine potency without creating new impurities or compromising the color specification.

Ready-to-use syringe strategy

A ready-to-use syringe can create more value than a conventional vial because it reduces preparation steps and dosing errors. Priority targets include:

• Emergency departments.
• Ambulatory surgery centers.
• Dental offices.
• Plastic surgery and dermatology clinics.
• Minor procedure kits.
• Hospital code and regional anesthesia carts.

The device must be compatible with the acidic, sulfite-containing solution and must maintain sterility and dose accuracy over shelf life. Syringe materials, elastomers, lubricant levels, plunger force, and needle integration can materially affect product performance.

What formulations are protected by patents?

The core active ingredients, lidocaine and epinephrine, are long-established molecules with no practical composition-of-matter exclusivity remaining for routine injectable combinations. Commercial protection is more likely to arise from:

• Specific concentration ratios.
• Preservative-free compositions.
• Sulfite-free stabilization systems.
• Prefilled syringe configurations.
• Dental cartridge systems.
• Long-term stability under defined oxygen or light conditions.
• Manufacturing processes that reduce epinephrine degradation.
• Combination kits containing the injection and a procedural device.
• Method-of-use claims directed to a particular procedure or patient population.

Patentability is stronger when a formulation produces a measurable technical effect, such as improved epinephrine stability, reduced discoloration, lower impurity formation, or improved syringe performance. A basic claim covering lidocaine hydrochloride, epinephrine, water, sodium chloride, and a conventional sulfite is likely to face substantial prior-art pressure.

The patent position should be analyzed at the product level. FDA Orange Book listings must be checked for the specific reference product and NDA. Injectable generic products can also be exposed to patents or exclusivity not obvious from a broad ingredient search, including formulation and device patents.[3]

When does lidocaine hydrochloride and epinephrine lose exclusivity?

The combination is generally beyond original small-molecule market exclusivity. Any remaining commercial barriers are more likely to involve product-specific patents, regulatory exclusivity, supply arrangements, or manufacturing constraints.

Exclusivity category	Relevance to this combination
New chemical entity exclusivity	Not relevant to established lidocaine and epinephrine
Five-year NCE exclusivity	Not applicable
Three-year new clinical investigation exclusivity	Possible only for qualifying new applications, not inherent in the old combination
Orphan-drug exclusivity	Generally not associated with routine local-anesthetic use
Pediatric exclusivity	Product-specific and uncommon as a decisive barrier
Patent exclusivity	Potentially relevant for newer formulations, devices, or methods
Biosimilar exclusivity	Not applicable
Generic competition	Established and commercially active

A generic applicant should evaluate the Orange Book, FDA-approved labels, patent declarations, state of approval, and litigation records for each reference-listed product. A Paragraph IV challenge may be relevant only if an unexpired listed patent covers the targeted reference product. For an old injectable combination, the greater risk is often technical equivalence and supply-chain execution rather than basic patent blocking.

Which companies are competing in lidocaine and epinephrine?

Competition spans branded innovators, generic injectable manufacturers, dental suppliers, and specialty device companies. Relevant commercial participants have included:

• Fresenius Kabi.
• Pfizer or Hospira legacy products.
• Hikma Pharmaceuticals.
• Sagent Pharmaceuticals and related corporate successors.
• Eugia Pharma Specialities.
• Akorn, where product and corporate status must be verified by current FDA records.
• Dentsply Sirona and other dental anesthetic suppliers.
• Septodont, particularly in dental cartridges.
• Regional injectable manufacturers and contract manufacturers.

The market is fragmented by dosage form. A supplier of hospital vials does not compete identically with a dental cartridge manufacturer or a prefilled syringe developer.

Hospital injection versus dental cartridge competition

Attribute	Hospital vial	Dental cartridge
Primary buyer	Hospital pharmacy, surgery center	Dental practice or distributor
Package size	Multi-dose or single-dose vials	Individual cartridges
Differentiation	Availability, preservative status, syringe compatibility	Cartridge quality, ergonomics, consistent delivery
Main quality risk	Sterility, shortage, stopper interaction	Breakage, leakage, plunger movement, needle compatibility
Commercial model	Tender, wholesaler, group purchasing	Dental distribution and practice-level purchasing

Dental products can command stronger presentation-based differentiation because cartridge dimensions, compatibility with aspirating syringes, packaging, and procedure workflow affect adoption.

What generic entry risks exist?

Generic entry risk is high for standard vial presentations because the products are mature, clinically familiar, and relatively straightforward to formulate. Risk is lower where the incumbent product has a differentiated device, proprietary cartridge, preservative-free profile, or difficult stability package.

High-risk segments for originator or incumbent revenue

• Standard 1% and 2% injections.
• 1:100,000 epinephrine strengths.
• Conventional multidose vials.
• Hospital products purchased through competitive tenders.
• Products with multiple approved generic equivalents.

Lower-risk segments

• Prefilled syringes.
• Ready-to-administer procedure kits.
• Sulfite-free or reduced-sulfite formulations.
• Premium preservative-free products.
• Specialized dental cartridges.
• Products with validated extended stability or low-waste packaging.

A generic launch can occur through several scenarios:

1. A conventional vial enters at a discount and competes primarily on availability.
2. A preservative-free product enters a hospital or specialty segment with a premium.
3. A device-integrated product obtains a narrower but higher-margin market.
4. A contract-manufactured product wins supply contracts after a shortage or discontinuation.
5. A dental cartridge supplier expands into adjacent strengths or geographic markets.

What patent litigation affects lidocaine and epinephrine?

No single litigation matter defines the entire lidocaine hydrochloride and epinephrine market. Litigation exposure is product-specific and may involve:

• Orange Book-listed formulation patents.
• Prefilled syringe or cartridge patents.
• Manufacturing-process claims.
• Labeling or method-of-use claims.
• Trade-secret disputes involving sterile injectable production.
• Contract-manufacturing and supply agreements.

For a conventional generic injection, a Paragraph IV dispute is less likely to be the principal barrier than a regulatory deficiency, stability failure, container-closure issue, or manufacturing inspection finding. For a differentiated product, the sponsor should expect patent scrutiny around antioxidant systems, oxygen management, delivery devices, and use-specific dosing.

Settlement agreements should be reviewed for:

• Authorized generic provisions.
• Entry dates.
• Supply commitments.
• Restrictions on strengths or package sizes.
• Licensing rights.
• Geographic scope.
• Manufacturing-source limitations.

Without a product-specific NDA and patent family, assigning a litigation outcome or expiration date would be inaccurate.

How strong is the patent estate for this combination?

The patent estate is weak for the basic drug combination and potentially moderate for engineered delivery formats.

Asset type	Estimated strategic strength
Lidocaine or epinephrine molecule patent	Very low
Conventional aqueous injection	Low
Standard sulfite-stabilized formulation	Low to moderate
Preservative-free formulation with demonstrated stability benefit	Moderate
Sulfite-free formulation with unexpected stability	Moderate to strong if data support non-obviousness
Prefilled syringe or cartridge system	Moderate
Integrated procedure kit	Moderate, depending on claim breadth
Manufacturing process with reproducible impurity control	Moderate
Method-of-use claim for standard local anesthesia	Low

The most defensible portfolio would combine composition claims with process, container-closure, and device claims. Patent term should be preserved through staggered filings only where each later filing contains genuinely new technical content. A patent strategy based solely on routine excipient substitution is vulnerable to obviousness challenges.

What commercial opportunities exist in excipients and formulation services?

Excipient suppliers can capture value in four areas.

Oxidation-control systems

Suppliers can provide validated sulfite grades, low-metal excipients, oxygen-control solutions, and analytical methods for epinephrine degradation. The value proposition is strongest when the excipient package reduces color formation or extends shelf life without increasing injection-site irritation.

Preservative-free manufacturing

Contract development and manufacturing organizations can offer aseptic filling into:

• Single-dose vials.
• Blow-fill-seal containers.
• Glass syringes.
• Polymer syringes.
• Dental cartridges.

The service opportunity is driven by shortage resilience, small-batch economics, and the need for specialized injectable facilities.

Device-compatible packaging

A package that maintains dose accuracy and chemical stability can differentiate an otherwise commoditized product. High-value features include low dead volume, integrated needle protection, tamper evidence, and compatibility with standard luer systems.

Stability and regulatory packages

A sponsor can commercialize a platform supported by comparative data across strengths and presentations. Stability packages should include assay, related substances, pH, color, particulate matter, sterility, endotoxin, container closure, and delivered dose where relevant.

How does lidocaine and epinephrine compare with plain lidocaine?

Criterion	Lidocaine alone	Lidocaine plus epinephrine
Anesthetic duration	Shorter in many local applications	Often prolonged
Bleeding control	Limited	Improved through vasoconstriction
Formulation complexity	Lower	Higher because epinephrine oxidizes
Excipient burden	Lower	Usually requires antioxidant control
Patient restrictions	Fewer vasoconstrictor-related restrictions	Greater caution in some cardiovascular or vascular conditions
Commercial differentiation	Limited	More opportunities through strength, package, and device
Manufacturing risk	Lower	Higher stability and color-control burden

The combination offers stronger procedural utility but creates more demanding quality-control requirements. That complexity supports premium products when the presentation solves a practical workflow or safety problem.

What geographic coverage and manufacturing barriers matter?

The active ingredients are globally established, but regulatory and commercial requirements differ by jurisdiction. Key variables include:

• Approved epinephrine ratios.
• Preservative labeling.
• Sulfite warning requirements.
• Dental cartridge standards.
• Injectable impurity limits.
• Sterility and endotoxin expectations.
• Pharmacopoeial requirements.
• Device registration where a syringe or cartridge is integral to administration.

Manufacturing barriers include sterile-facility capacity, reliable epinephrine raw-material supply, low-oxygen filling, validated cleaning for potent color-forming compounds, and container-closure control. Injectable shortages can create significant commercial openings for a supplier with redundant manufacturing sites and established regulatory files.

Key Takeaways

• The core lidocaine and epinephrine combination has little practical molecule-level exclusivity.
• Standard vial products face high generic-entry risk and price competition.
• Epinephrine oxidation is the primary formulation challenge.
• Sodium metabisulfite is commercially effective but creates sulfite-related labeling and positioning issues.
• Preservative-free, sulfite-reduced, and ready-to-use formats offer the clearest differentiation.
• Device, cartridge, packaging, and manufacturing-process patents are more valuable than basic composition claims.
• The highest-value commercial opportunities are in dental cartridges, prefilled syringes, procedure kits, and reliable hospital supply.
• No biosimilar pathway applies because the product is a small-molecule injectable.
• Product-specific Orange Book, patent, and litigation analysis is required before assigning expiration dates or Paragraph IV exposure.

FAQs

Is lidocaine with epinephrine available as a preservative-free injection?

Some single-dose injectable products are preservative-free, but the status depends on the specific manufacturer, strength, and package. Multidose products may contain a preservative. The approved label should control the formulation determination.[2]

Can sodium metabisulfite be removed from lidocaine with epinephrine?

It can be explored, but removal requires an alternative stability strategy. Epinephrine potency, color, degradation products, oxygen exposure, and shelf life must be demonstrated through a complete injectable stability program.

Are there biosimilars for lidocaine hydrochloride and epinephrine?

No. Lidocaine hydrochloride and epinephrine is a small-molecule drug combination. Competition is generally through generic injectable applications rather than biosimilar applications.

Is lidocaine with epinephrine protected by an active composition patent?

The basic combination is generally too old for original composition-of-matter protection. Active patents may still cover specific formulations, devices, manufacturing processes, or methods of use.

Which product format offers the strongest commercial differentiation?

Prefilled syringes, preservative-free unit-dose products, specialized dental cartridges, and validated sulfite-free or reduced-sulfite formulations offer more differentiation than conventional multidose vials.

References

1. U.S. Food and Drug Administration. (n.d.). Lidocaine hydrochloride and epinephrine injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. National Library of Medicine. (n.d.). DailyMed drug labels: Lidocaine hydrochloride and epinephrine. https://dailymed.nlm.nih.gov/dailymed/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (2015). Safety and performance based pathway: Guidance for industry and FDA staff. https://www.fda.gov/

5. International Council for Harmonisation. (2003). ICH Q1A(R2): Stability testing of new drug substances and products. https://www.ich.org/.page/quality-guidelines.html